The pharmaceutical price regulation scheme

Article Abstract:

The British government influences the pharmaceutical market through a mixture of micro and macroeconomic regulations. Such micro policies include declassifying medicines from prescription to nonprescription and decreasing the number of drugs eligible for National Health Service reimbursement. The macro-regulatory initiative, the Pharmaceutical Price Regulation Scheme (PPRS), regulates price increases, profits, R&D expenditure and advertising budget. Analysis of the PPRS reveals a number of weaknesses, including lack of accountability, lack of impact analysis and uncertainty regarding its alignment with EU law.

Pharmaceutical Preparations, Price & Wage Controls, Laws, regulations and rules, Pharmaceutical industry, Drugs, Price control, Price regulations, Wage price policy

---

MILLENNIUM PLANS TO PAY $52M FOR TEAM OF OXFORD CHEMISTS

Article Abstract:

Cambridge Discovery Chemistry To bolster what Millennium Pharmaceuticals Inc. calls its "gene-to- patient" drug discovery platform with a small army of new scientists dedicated to medicinal chemistry, the company said it plans to acquire Cambridge Discovery Chemistry (CDC), a wholly owned subsidiary of Oxford Molecular Group plc, for about $52.7 million (oe35 million).

United Kingdom, Asset sales & divestitures, Acquisitions & mergers, Chemicals & Allied Products, Chemical Manufacturing, CHEMICALS AND ALLIED PRODUCTS, Computer integrated systems design, In-House Computers Services, Computer Systems Design Services, Information technology services, Brief Article, Chemicals, Millennium Pharmaceuticals Inc., MLNM, Oxford Molecular Group PLC, Cambridge Discovery Chemistry

---

OTHER NEWS TO NOTE

Article Abstract:

Genta Inc., Small Business Innovation and Research grant

United States, Product development, Financial management, Biological Product (except Diagnostic) Manufacturing, Drugs, Alliances, partnerships, Biological Products, Anticancer Drugs, Ophthalmic Drugs, Small Business Aid Programs, Antineoplastic agents, Elan Corporation PLC, Human Genome Sciences Inc., HGSI, Ophthalmic agents, Small business assistance, Genta Inc., Aviron, Acqua Wellington Asset Management LLC, Infectech Inc., NeoPharm Inc., North American Vaccine Inc., Ciba Vision Corp., Baxter International Ltd., PPGx Inc., QLT Phototherapeutics Inc., Transgene SA, VION Pharmaceuticals Inc., GNTAC, AVIR, NEO, NVX, LIPO, VION

Similar abstracts:

• Abstracts: Brewers ready for a stubby price war CZECH REPUBLIC: PLANS TO PROTECT PILSNER LAGER
• Abstracts: Brewers ready for a stubby price war UK: SOUTH AFRICAN WINES TO DEBUT. UK: NEW CHILDREN'S TOOTHBRUSH FROM WISDOM
• Abstracts: FIRM HITS HOME RUN WHEN IT COMES TO CUSTOMER SERVICE. ONLINE GROUPS SEEM OUT OF FOCUS TO SOME TRADITIONAL RESEARCHERS
• Abstracts: A behavioural analysis of co-operative marketing organisations. Female employment in sales organisations: Learning to manage the 'pink collar' army
• Abstracts: A crisis of credibility? Polish crisis that needs Western solidarity. Crisis, what crisis?

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.